United-Guardian, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 16, 2022. The filing is an annual report, not a standalone fourth-quarter report, so it does not provide clear Q4-only financial results.
Business context
United-Guardian manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products through its Guardian Laboratories division. Its largest product lines are Lubrajel and Renacidin. The company operates as one business segment and depends on marketing partners, including Ashland Specialty Ingredients (ASI), to distribute many cosmetic products.
Key financial results
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Net sales | $13.93 million | $10.99 million |
| Gross margin | 59% | 56% |
| Operating income | $5.67 million | $3.64 million |
| Net income | $4.66 million | $3.30 million |
| Diluted and basic EPS | $1.01 | $0.72 |
| Cash from operations | $5.31 million | $3.59 million |
| Cash and cash equivalents, year-end | $0.53 million | $0.59 million |
| Marketable securities, year-end | $7.64 million | $7.59 million |
| Working capital, year-end | $9.25 million | $9.83 million |
| Current ratio | 5.0:1 | 8.0:1 |
Sales rose 27%. Cosmetic ingredient sales increased 61% to $6.87 million, primarily from higher Lubrajel sales to ASI. Pharmaceutical net sales increased to $4.74 million from $4.52 million, despite lower gross pharmaceutical sales, as rebate and allowance deductions declined. Medical product sales increased 6% to $2.17 million; industrial and other sales were $0.15 million. Gross margin improved with a greater contribution from higher-margin Lubrajel products and reduced pharmaceutical allowances.
Operating expenses were $2.04 million, slightly above 2020; research and development expense was $0.48 million versus $0.45 million. Income tax expense was $1.22 million, at a 20.7% effective rate. Investment income was $0.23 million, while the company recorded a $0.02 million net loss on marketable securities, compared with a $0.30 million gain in 2020.
Cash used in investing activities was $0.18 million; cash used in financing was $5.19 million, mainly reflecting dividends. Dividends declared were $1.13 per share in 2021, versus $0.78 in 2020. The balance sheet shows no borrowings or debt; current liabilities were $2.34 million, and total assets were $12.24 million. The company reported that working capital was sufficient for the next fiscal year and that it had no material capital-expenditure commitments.
Material changes and developments
- Renacidin gross sales declined 6% to $5.04 million after the company ended participation in Medicaid Drug Rebate and 340B programs effective December 31, 2020. Lower rebates and allowances more than offset lost sales and increased Renacidin gross profit. The company continues to participate in Veterans Affairs and Medicare discount programs.
- ASI purchases represented approximately 40% of total company sales in 2021, compared with 29% in 2020. Four distributors and marketing partners together accounted for about 75% of gross sales and 80% of year-end receivables.
- The company paid higher dividends, contributing to lower working capital and a 5.0:1 current ratio, down from 8.0:1.
- Subsequent to year-end, the board initiated a formal review of strategic alternatives, potentially including a sale, joint ventures, partnerships, or other transactions. The company retained Capstone Partners and paid a $75,000 non-refundable fee. No outcome is assured.
Outlook, commentary, and risks
Management said pandemic-related sales impacts eased in 2021, but could not reliably project the pandemic’s future effects. Higher raw-material, freight, and labor costs; shipping delays and shortages; and inflation could pressure margins. The company expected shipping constraints to persist into 2022, with improvement as the year progressed. Management anticipated operating expenses to remain relatively consistent and R&D spending in 2022 to be comparable to 2021; it expected to introduce several new products during 2022.
Other risks include lower-priced Asian and European competitors, currency movements that can reduce overseas competitiveness, reliance on ASI and a small number of customers and distributors, and concentration among six major raw-material vendors representing 94% of 2021 purchases. The company disclosed a temporary disruption at one raw-material supplier and was qualifying a second source. Product development is uncertain, and the company does not plan to develop new drugs or medical devices. It relies primarily on trade secrets rather than patents; its prior patents have expired.
The company reported no legal proceedings, no material environmental-law impact, and no off-balance-sheet transactions. Management concluded disclosure controls and internal control over financial reporting were effective; the external auditor reported no critical audit matters and did not audit internal-control effectiveness. Approximately $410,000 of cash deposits exceeded FDIC insurance limits.
Important facts for investors to verify
- Progress and eventual outcome of the strategic-alternatives review, including any costs, transaction terms, or changes in direction.
- Whether ASI’s increased purchases are sustained and how customer and distributor concentration affects revenue and receivable risk.
- Renacidin sales, profitability, and rebate obligations following withdrawal from Medicaid and 340B programs.
- Whether freight, raw-material, labor, and inflationary pressures affect margins, and whether the alternate raw-material source is qualified.
- Commercial adoption and financial contribution of the new Lubrajel and other pipeline products; development success and sales are not assured.
- Cash and marketable-securities values, portfolio fluctuations, dividend sustainability, and the amount of cash above FDIC limits.